Portfolio Companies News
February 21, 2017GenSight Biologics Completes Enroll...
Paris, France, February 21, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today ... read more
February 20, 2017Orexo Completes Bond Buyback Progra...
Uppsala, Sweden – February 20, 2017 – Orexo AB (publ.) announces that it has successfully completed a limited bond buyback program and in total purchased Orexo corporate bonds in the market with a nominal value of MSEK 59. The program was initiated on February 8, 2017, and completed by February ... read more
February 17, 2017Publishing of Nexstim Plc 2016 Full...
17 February 2017 Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company with a pioneering navigated non-invasive brain stimulation system, will announce its full year results for the year ended 31 December 2016 in the morning of Monday 28 February 2017. A conference call for analysts... read more
February 17, 20172016 ANNUAL RESULTS
Solid cash position of €24.7 million and finalization of CARAT phase 2 clinical study Toulouse, France, Ann Arbor, United States, February 17 2017 – 6 pm CET – Cerenis Therapeutics (FR0012616852- CEREN), an international biopharmaceutical company dedicated to the discovery and development o... read more
February 16, 2017Targovax ASA: Fourth quarter and fu...
Oslo, Norway, 16 February 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its fourth quarter and full year 2016 results. A meeting for investors, analysts and press will... read more
February 06, 2017Q4 2016 General Market Overview